1873 — VIVA Biotech Holdings Income Statement
0.000.00%
Last trade - 00:00
- HK$1.29bn
- HK$1.85bn
- CNY2.16bn
- 53
- 62
- 31
- 46
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 323 | 697 | 2,104 | 2,380 | 2,156 |
Cost of Revenue | |||||
Gross Profit | 156 | 305 | 651 | 816 | 738 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.73 | 443 | 1,711 | 2,664 | 2,209 |
Operating Profit | 319 | 253 | 393 | -285 | -53.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 281 | -356 | 348 | -459 | -56 |
Provision for Income Taxes | |||||
Net Income After Taxes | 266 | -379 | 301 | -504 | -99.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 266 | -387 | 288 | -528 | -116 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 266 | -387 | 163 | -528 | -116 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.183 | -0.243 | 0.081 | -0.259 | 0.017 |
Dividends per Share |